New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.

نویسندگان

  • Toshihide Harada
  • Fumiko Ishizaki
  • Nobuko Horie
  • Yumiko Nitta
  • Tohru Yamada
  • Tomohiro Sasaki
  • Tomoomi Nagakane
  • Yoshiteru Yasumatsu
  • Kohsaku Nitta
  • Hiroyuki Katsuoka
چکیده

Previous studies have shown that pramipexole might have the potential to improve depressive symptoms in patients with Parkinson's disease. To provide more evidence, in five Japanese patients at Hoehn & Yahr stage 1-3 we evaluated the Unified Parkinson's Disease Rating Scale (UPDRS), Hamilton Depression Rating Scale (HAMD) and Montgomery Asberg Depression Rating Scale (MADRS) at our hospital. After the pramipexole treatment, each total score of UPDRS, HAMD and MADRS significantly decreased compared with that before the treatment. Our data indicate that pramipexole improves depressive symptoms in patients with Parkinson's disease.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Role of pramipexole in the management of Parkinson's disease.

The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic ef...

متن کامل

The effect of pramipexole on depressive symptoms in Parkinson's disease.

Depression is a common occurrence in patients with Parkinson's disease (PD). Pramipexole is a dopamine agonist that has been used to treat both motor and non-motor symptoms associated with PD. We conducted a study to elucidate the effect of pramipexole on each of the depressive symptoms as assessed by the Zung Self-Rating Depression Scale (SDS). Twenty patients with PD were treated with pramipe...

متن کامل

Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.

OBJECTIVE The long-term use of levodopa to treat Parkinson's disease (PD) is often limited by the development of motor complications (e.g., levodopa-induced dyskinesia, LID). We hypothesized that a non-ergot dopamine agonist with strong affinity for D3) dopamine receptors (pramipexole) may improve LID in patients taking an ergot D1/D2 dopamine agonist. METHODS Patients with PD and LID being t...

متن کامل

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available for symptomatic treatment...

متن کامل

Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.

OBJECTIVE We studied the prevalence and related risk factors of impulse control disorders in Chinese Parkinson's disease patients. METHOD We screened all non-demented Parkinson's disease patients attending our Parkinson's disease clinic from August 2009 to March 2010. The clinical characteristics of patients with impulse control disorders and those without were compared. RESULTS Of the 213 ...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Hiroshima journal of medical sciences

دوره 60 4  شماره 

صفحات  -

تاریخ انتشار 2011